Lincoln Pharmaceuticals Share Price Gains Over 4% After Q1 FY27 Earnings Results: Total Income Up 19% YoY

On August 13, 2026, Lincoln Pharmaceuticals Limited released its consolidated unaudited financial results for the quarter ended June 30, 2026. The reported data highlights the income and profit performance of the company across yearly and quarterly intervals. 

Lincoln Pharmaceuticals Q1 FY27 Earnings Results 

For the quarter ended June 30, 2026, Lincoln Pharmaceuticals Limited recorded a total income of ₹201.55 crore. This figure represents a 19.0% increase compared to the ₹169.34 crore reported for the same period in the previous year.  

On a sequential basis, the total income grew by 10.1% from the ₹183.08 crore recorded in the March 2026 quarter. 

The company net profit for the June 2026 quarter was ₹36.23 crore. This reflects a 30.9% increase over the ₹27.68 crore reported during the corresponding quarter of the previous year.  

When measured against the preceding quarter, the net profit moved from ₹11.63 crore in March 2026 to ₹36.23 crore in June 2026, marking a 211.4% increase. 

Annual Performance for FY26 

In addition to the quarterly figures, the company provided financial data regarding the preceding fiscal year. For the full year of 2026, the total income of Lincoln Pharmaceuticals Limited stood at ₹704.48 crore. During this same period, the net profit, or profit after tax, was reported as ₹87.89 crore. 

Key Business Highlights 

The firm is targeting a revenue milestone of ₹1,000 crore over the next three years. It aims to sustain a steady fifteen to eighteen percent annual growth rate. 

The organization remains completely net-debt free with strong financial health. Furthermore, Foreign Institutional Investors expanded their equity holdings in the company to four point six zero percent. 

Global Footprint and Compliance 

The company currently exports its pharmaceutical formulations to over sixty global countries. It plans to aggressively expand its market presence to ninety countries within the next three years. 

The growth is backed by entry into Canada along with European Union GMP approvals. It also holds prestigious certifications from TGA Australia and WHO-GMP. 

Read More: Zomato’s District Expands Beyond Dining: What Is Eternal Planning? 

Research and Operations 

The enterprise boasts a diversified portfolio featuring over six hundred unique formulations across fifteen distinct therapeutic segments. It currently has seven hundred additional products under development. 

The business operates advanced manufacturing units in Khatraj and Mehsana, Gujarat. It utilizes solar plants and windmills to run nearly one hundred percent green renewable energy operations. 

Lincoln Pharmaceuticals Share Price Performance 

As of August 13, 2026, at 1:49 PM, Lincoln Pharmaceuticals share price on NSE was trading at ₹617.00, up by 4.07% from the previous closing price. 

Conclusion 

Lincoln Pharmaceuticals recorded a total income of ₹201.55 crore and a net profit of ₹36.23 crore for the quarter ended June 30, 2026. Annual totals for 2026 include income of ₹704.48 crore and profit of ₹87.89 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.